Acota

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acota

Understanding Acota

Acota is a therapeutic agent that contains the active substance acotiamide. It belongs to a class of medications known as prokinetics, which are designed to enhance the movement and motility of the gastrointestinal tract.

Mechanism of Action

The primary function of Acota is to improve the muscular activity of the stomach. It works by increasing the availability of acetylcholine, a chemical messenger in the nervous system that signals the muscles in the digestive tract to contract. By inhibiting the breakdown of this messenger, Acota helps the stomach to empty more efficiently and facilitates the downward movement of food through the digestive system.

Therapeutic Use

Acota is primarily used to manage symptoms associated with functional dyspepsia. This is a condition characterized by chronic or recurrent pain or discomfort in the upper abdomen, often occurring after eating. Unlike other digestive disorders, functional dyspepsia does not involve visible inflammation or structural abnormalities in the digestive tract.

Patients may be prescribed this medication to address several specific sensations, including:

  • Postprandial fullness: An uncomfortable sensation that food is remaining in the stomach for an unusually long period.
  • Upper abdominal bloating: A feeling of pressure or swelling in the stomach area after meals.
  • Early satiety: Feeling full shortly after beginning a meal, regardless of the amount of food consumed.

By improving gastric motility and accommodation—the ability of the stomach to relax and expand when food enters—Acota aims to reduce the physical discomfort associated with impaired digestion.

Regulatory References

  1. European Public Assessment Reports (EPARs) - EMA

What side effects are possible with Acota?

Official Safety Profile of Acota (Aceclofenac)

The official safety profile for Acota, an NSAID, is structured by regulatory bodies to classify potential adverse reactions based on frequency and affected physiological system. The most commonly reported adverse reactions are typically related to the Gastrointestinal system and include effects classified as Common, such as dyspepsia, abdominal pain, and nausea, and Uncommon effects like gastritis or rash.

Adverse Reaction Frequencies and Systems

Classification Example Effects (System-Organ Class)
Common Dizziness (Nervous system), Nausea, Abdominal Pain (Gastrointestinal), Increased Hepatic Enzymes (Hepatobiliary)
Uncommon Pruritus, Rash (Skin), Vomiting, Flatulence (Gastrointestinal), Increased Creatinine (Renal and Urinary)
Rare Anaphylactic Reactions (Immune system), Gastrointestinal Ulceration and Haemorrhage (Gastrointestinal)
Very Rare Severe Bullous Reactions like SJS/TEN (Skin), Renal Failure (Renal and Urinary), Cardiac Failure (Cardiac)

Serious Adverse Reactions and Safety Considerations

The regulatory documentation highlights several potentially Serious Adverse Reactions, including gastrointestinal bleeding, ulceration, or perforation, which can occur at any time during treatment. Severe hepatic reactions and severe dermatological reactions like Stevens-Johnson Syndrome are also officially listed as Very Rare events.

Safety notes emphasize that certain risks are elevated for defined patient groups. Older adults have an increased frequency and severity of adverse reactions, particularly serious gastrointestinal events. Furthermore, the risk of serious events, including cardiovascular thrombotic events, is associated with longer duration of treatment and higher dosages. Official restrictions apply to patients with active peptic ulceration/haemorrhage or confirmed severe heart, liver, or renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Acota (Aceclofenac) overdose details specific clinical manifestations and mandates immediate emergency action.

Documented Manifestations Severe Outcomes
Gastrointestinal bleeding, vomiting, epigastric pain, headache, dizziness, disorientation, and convulsions. Acute renal failure, Liver damage, Coma, and Respiratory depression.

Emergency Response and Management

The potential for life-threatening events, including acute renal failure and severe CNS depression, means that immediate medical attention must be sought if an overdose is suspected. Specific documented effects may also include hypotension and generalized gastrointestinal irritation.

No specific antidote is known for Aceclofenac overdose. Therefore, management is officially classified as symptomatic and supportive treatment. Procedural interventions listed in the regulatory documents include the consideration of activated charcoal or gastric lavage (in adults) within one hour of ingesting a potentially toxic amount. Observation for at least four hours is required following ingestion of a toxic quantity. Furthermore, Intravenous diazepam is the specified intervention for the treatment of frequent or prolonged convulsions.

Therapeutic Uses of Acota

What Acota Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed for symptoms related to physical discomfort and irritative processes. It generally provides support that helps ease the overall symptom burden, assisting patients with managing difficult episodes. Its use is considered relevant across therapeutic areas involving heightened responses.

Acota is commonly used across conditions presenting with systemic or localized discomfort, such as those involving Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Osteoarthritis (OA), and certain presentations of low back pain. It helps address symptom clusters that may become intense or disruptive in conditions characterized by periods of heightened symptoms.

“It provides supportive relief when symptoms interfere with routine activities, contributing to improved day-to-day comfort.”

It is also relevant in contexts marked by increased discomfort or tension arising from conditions like extraarticular rheumatism and is often used during phases when symptoms become temporarily overwhelming, such as in situations involving dental pain or gynaecological pain.

Quick Fact: Supportive Relief for Discomfort
Relevant Domain: Musculoskeletal and Chronic Joint Pain
Symptom Axes: Pain, Swelling, and Functional Stiffness
Supportive Benefit: Assists with maintaining functional stability

Regulatory References

  1. UK Medicines and Healthcare products Regulatory Agency Guidance

Eligibility and Restrictions for Use

Who can and cannot use Acota?

The eligibility profile for Acota (Aceclofenac), an NSAID, is strictly defined by regulatory documents based on contraindications and the availability of safety data across patient populations.

Category Eligibility Rule
Absolute Contraindications Contraindicated in patients with known hypersensitivity to the drug or other NSAIDs (e.g., aspirin), severe hepatic or renal failure, active GI bleeding, or recurrent peptic ulceration.
Cardiovascular Status Contraindicated in individuals with established Congestive Heart Failure (NYHA Class II-IV), Ischaemic Heart Disease, Peripheral Arterial Disease, and/or Cerebrovascular Disease.
Age and Pregnancy Contraindicated during the third trimester of pregnancy. Use is not recommended in children and adolescents under 18 years due to the absence of established safety and efficacy data.

The regulatory profile specifies that use requires caution and monitoring for specific groups. These include older adults, individuals with mild-to-moderate renal or hepatic impairment, and patients with mild Congestive Heart Failure (NYHA Class I). Eligibility is thus determined by the absence of severe disqualifying conditions and adherence to documented age and physiological status restrictions.

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Aceclofenac primarily through two core mechanisms: increased organ-system toxicity and the inhibition of co-administered drug clearance.

Interaction Classification Interacting Agents (Official Constraint)
Formal Avoidance Other NSAIDs and COX-2 inhibitors (concomitant use must be avoided). Aspirin (contraindicated in patients with hypersensitivity history).
Increased Bleeding Risk Anticoagulants (Warfarin), Corticosteroids, SSRIs, and Antiplatelet Agents (requires close monitoring due to heightened risk of GI bleeding or ulceration).
Renal / Blood Risk Diuretics and Antihypertensives (reduced efficacy and increased risk of acute renal insufficiency, especially in elderly or compromised patients). Cyclosporin (enhanced nephrotoxicity risk). Alcohol (requires surveillance due to gastric bleeding potential).

Interactions resulting in modified exposure are formally documented for certain substances. Aceclofenac inhibits the renal clearance of both Lithium and Digoxin, leading to an officially documented increase in their serum concentrations. Similarly, co-administration may increase Methotrexate plasma levels, potentially resulting in toxicity; a temporal separation of 2–4 hours is a documented constraint. The combination with Quinolone antibiotics is noted for increasing the risk of convulsions. The profile is marked by mandatory avoidance rules for combining it with other NSAIDs and specific timing requirements for a limited number of other medicines.

Mechanism of Action

How Acota Works

Acota (acetazolamide) is a selective inhibitor that exerts its effects by acting within two primary mechanistic domains, resulting in defined physiological changes. The drug's action is defined by modifying key enzymatic pathways, resulting in downstream effects on fluid dynamics and neuronal excitability.

Targeted Inhibition of Carbonic Anhydrase

Acota's core mechanism is the inhibition of the enzyme carbonic anhydrase (CA), an enzyme central to acid-base balance and ion transport. This targeted effect within enzyme-mediated signaling blocks the rapid conversion of carbon dioxide ( CO2) and water ( H2 O) into bicarbonate ( HCO3^-) and H^+. This initial molecular step modifies key pathways associated with ion movement in multiple biological systems.

Modulation of Fluid Dynamics and Neural Activity

The mechanistic cascade initiated by CA inhibition leads to two distinct physiological consequences. In the kidney, it increases the excretion of bicarbonate and associated electrolytes, which results in the alteration of fluid volume and electrolyte composition. In the central nervous system (CNS), the resulting local changes in CO2 concentration and pH influence core regulatory systems to modify the frequency and amplitude of neuronal discharge. These actions constitute the mechanism for the drug's observable effects.

Dosage and Administration Information

How to Use Acota

Acota is supplied as a 100 mg film-coated tablet intended for oral administration, and its use follows established dosing and procedural protocols. The guidelines emphasize using the lowest effective dose for the shortest duration necessary to control symptoms, consistent with standard approaches for Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).


Standard Dosing and Intake Conditions

Feature General Administration
Route of Administration Oral (by mouth)
Standard Daily Dose 200 mg total
Dosing Schedule Taken as two separate 100 mg doses per day (twice daily)
Intake Condition Tablets should be swallowed whole with liquid, preferably with or after food
Duration Principle Use for the shortest duration necessary; re-evaluate need periodically

Population-Specific Adjustments

Prescribing information outlines specific high-level rules for certain patient populations:

  • Hepatic Impairment: Patients with mild to moderate liver impairment should have their initial dose reduced to 100 mg daily.
  • Renal Impairment: Generally, no dose modification is necessary for patients with mild kidney impairment.
  • Older Adults (Elderly): No specific dose modification is required, but the lowest possible dose should be used due to general caution associated with age.
  • Pediatric Patients: Acota is not recommended for use in children and adolescents, as there is insufficient clinical data to support its use in these age groups.

Recent Clinical Evidence

Research evidence / Overview of studies for Acota

Evidence for use in Chronic Joint Conditions (Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis)

Research studies evaluating Aceclofenac have been conducted primarily through short-term randomized controlled trials (RCTs) and meta-analyses in adults with long-term conditions like Osteoarthritis (OA), Rheumatoid Arthritis (RA), and Ankylosing Spondylitis (AS). Research examined outcomes related to physical discomfort and functional imbalance. For these chronic conditions, studies evaluated scores of pain intensity, joint stiffness, and functional capacity (e.g., WOMAC scores for OA). Studies reported measurements of pain levels and stiffness during the study period compared to placebo and other active pain relievers. The evidence structure is primarily short-term, meaning long-term functional outcomes or effects on disease progression are not well characterized by existing RCTs.


Evidence for use in Acute Pain and Musculoskeletal Sprains

Aceclofenac was studied for short-term symptomatic changes in acute or disruptive episodes, such as dental pain and low back pain, typically employing single-dose or very short-term trial designs. In these settings, the research focused on outcomes related to episodic changes. Researchers monitored the period during which individuals reported pain intensity scores and whether they needed rescue analgesia. Findings described patterns related to measured pain scores during these acute scenarios, but these results apply only to the specific, short timeframes of the trials and do not offer information about ongoing chronic pain management.


Research Gaps and Special Populations

The majority of high-quality research was evaluated in broad adult populations. Findings for subgroups defined by age (e.g., older adults) or by the presence of other illnesses are uncertain because sample sizes were typically small within these specific strata. Follow-up durations were limited in many RCTs, meaning the research provides limited insight into the sustained symptomatic patterns over several years. Data are still emerging for a consistent and detailed understanding of how Aceclofenac is associated with outcomes in many special populations.

Key Studies & References

  1. Aceclofenac (Preservex): updated cardiovascular advice in line with diclofenac and COX-2 inhibitors - Regulatory Safety Update
  2. A Review of Aceclofenac: Analgesic and Anti-Inflammatory Effects on Musculoskeletal Disorders

Frequently Asked Questions (FAQ)

Common questions about Acota (FAQ)

Q: Is Acota used for anything other than its main approved condition?

A: Official documents describe Acota's use for the relief of pain and inflammation associated with chronic joint conditions. These conditions commonly include osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. Your healthcare provider relies on this official information when determining the appropriate use.

Q: What happens if I miss a scheduled time to take Acota?

A: Official guidance states that if a dose is missed, it should be taken as soon as remembered. However, if it is nearly time for your next scheduled dose, it is specified that the missed dose should not be doubled.

Q: Is it possible to become dependent on Acota?

A: Acota's active ingredient, Aceclofenac, is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID) and is not a narcotic. Regulatory documents do not formally categorize this medicine as a substance associated with physical dependence.

Q: Are there specific side effects of Acota I should watch out for?

A: Official safety information highlights the need to monitor for signs of serious, though rare, reactions such as gastrointestinal bleeding or ulceration, as well as severe skin reactions. The official documentation mentions monitoring for signs of immediate hypersensitivity, such as facial swelling or difficulty breathing.

Q: Does Acota cause weight gain or weight loss?

A: Like other medicines in the NSAID class, Acota may be associated with fluid retention or edema, which is a potential side effect listed in official documents. Fluid retention can sometimes lead to an increase in body weight.

Q: Is Acota known to cause trouble sleeping or drowsiness?

A: The official safety profile lists drowsiness as a possible effect on the nervous system. This is noted as one of the potential adverse reactions that may be experienced while taking this medicine.

Q: Can Acota affect my mood or mental clarity?

A: Adverse reactions listed in official regulatory documents include nervous system effects such as dizziness and headache. Specific changes in mood or general mental clarity are not explicitly listed in common safety reports, though side effects may vary.

Q: Is it safe to drive or operate machinery while taking Acota?

A: Regulatory warnings state that if a patient experiences nervous system effects like dizziness or vertigo, they should avoid driving or operating machinery. These effects are noted to potentially impact physical coordination and concentration.

Q: Are there any age limits for who can use Acota?

A: Regulatory documents state that Acota is not recommended for use in children and adolescents under 18 years because of insufficient clinical data on safety and efficacy in these age groups. For older adults, the lowest effective dose is advised due to a generally increased risk of adverse reactions.

Q: Does Acota interact with common cold or flu medicines?

A: Official interaction guidance warns against the concomitant use of Acota with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Because NSAIDs are common active ingredients in many over-the-counter cold and flu preparations, it is important to be aware of this formal avoidance constraint.

Q: Is it safe to take Acota while pregnant or trying to conceive?

A: Acota is formally contraindicated (must not be used) during the third trimester of pregnancy. For use during the first and second trimesters, or when trying to conceive, official documents note that use during these periods requires individual guidance from a healthcare provider due to potential risks.

Q: Can Acota pass into breast milk if I am nursing?

A: Official documents note that the use of Acota during breastfeeding is generally not recommended unless use is determined to be essential by a healthcare provider. This cautious approach is taken because it is uncertain if the drug is excreted in human breast milk.

Q: What type of medical professional typically prescribes Acota?

A: Acota is generally classified as a prescription-only medicine (POM). This means it is prescribed by a licensed healthcare professional, such as a medical doctor, specialist, or other authorized prescriber.

Q: Is the dose of Acota adjusted based on body weight?

A: Official dosing guidelines outline standard doses and specific adjustments based on a patient's liver (hepatic) and kidney (renal) impairment status, as well as for older adults. Dose modifications based specifically on a patient's body weight are not defined in the regulatory documentation for this product.

Q: Is there a maximum time someone is allowed to take Acota?

A: Regulatory guidance emphasizes that Acota should be used for the shortest duration necessary and at the lowest effective dose. This is due to safety risks, including cardiovascular thrombotic events, which are associated with longer treatment duration and higher dosages.

Q: Why does the package insert for Acota list so many potential side effects?

A: Regulatory agencies require that package inserts must include all potential adverse effects observed during clinical trials. These effects are classified by their frequency, such as common or rare, to ensure all possible reactions are documented for patient awareness, even those that occur infrequently.

Q: Does Acota affect fertility in men or women?

A: For women who are trying to conceive, official safety documents advise that, like other NSAIDs, Acota may transiently impair fertility by interfering with ovulation. This effect is described as reversible when the medicine is stopped.

Q: Is it important to take Acota at the exact same time every day?

A: Official instructions recommend taking the medication twice daily, such as in the morning and evening, with or after food. While consistency is encouraged to maintain stable effects, the documentation specifies the required frequency, not a strict, minute-by-minute time requirement.

Q: Do children and adolescents use Acota for the same conditions as adults?

A: Regulatory documents state that Acota is not recommended for use in children and adolescents because there is insufficient clinical data to support its safety and efficacy in these age groups for any condition.

Q: Can Acota affect a person's ability to concentrate?

A: The official safety profile includes nervous system adverse effects such as dizziness and drowsiness. These reported effects may interfere with a person's ability to focus or concentrate.

Q: Does Acota interact with birth control pills?

A: Studies have described that the use of NSAIDs like Acota alongside certain hormonal birth control methods may increase the potential risk of developing Venous Thromboembolism (VTE). This is a potential interaction noted in regulatory data.

Q: Does Acota have any known black box warnings?

A: In the United States, all systemic Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) carry an official Boxed Warning. This is the highest level of caution from the FDA regarding the potential for serious cardiovascular events (like heart attack or stroke) and serious gastrointestinal adverse events.

Q: How does taking Acota affect routine blood tests?

A: Official safety reports list changes in certain laboratory values as possible adverse reactions reported during treatment. Specifically, these may include increased hepatic (liver) enzymes and increased serum creatinine, which is a marker for kidney function.

Q: Can Acota cause changes in blood pressure?

A: Regulatory warnings for Acota, as with other NSAIDs, note that the medicine may cause elevated blood pressure or potentially worsen existing hypertension. It is also noted that it can interfere with the effectiveness of certain blood pressure medications.

Q: Are there any major diet restrictions when taking Acota?

A: Regulatory documentation only provides instructions to take Acota with or after food and cautions against the concomitant use of alcohol. There are no other major dietary restrictions specifically described in the official product information.

Q: How quickly can someone expect Acota to start working?

A: Pharmacokinetic studies, which describe how the drug moves through the body, indicate that the peak concentration (C max) of the active ingredient is generally reached within 1 to 2 hours after taking the tablet.

Q: How long do the effects of Acota last after taking it?

A: The active ingredient in Acota has a plasma half-life of approximately 4 hours. This measure describes the time required for the amount of medicine in the body to decrease by half.

Q: Are there long-term safety studies available for Acota?

A: While many controlled clinical trials for efficacy were short-term, regulatory agencies conduct ongoing post-marketing surveillance and have collected safety data for Acota over extended periods. However, the evidence from controlled, long-term functional studies is described as limited.

Q: What is the difference between how Acota works and how older drugs worked for the same condition?

A: Acota's active ingredient, Aceclofenac, is chemically related to Diclofenac and is classified as an NSAID. It is described as having a comparable or higher anti-inflammatory effect while demonstrating potential for improved gastrointestinal tolerability compared to some older NSAIDs.

Q: Can Acota be taken with common vitamins or supplements?

A: Official product information lists known interactions with prescription and over-the-counter medicines. However, it does not specify any major formal contraindications for its use with common vitamins or general nutritional supplements.

How should Acota be stored and disposed of?

How to Store and Dispose of Acota?

The official instructions for storing and disposing of Acota (Aceclofenac) are designed to maintain its stability and protect the environment, according to regulatory documents.


Storage Requirements

  • Temperature and Light: Acota tablets must be stored below 30 C and should be kept in the original package to ensure protection from light and maintain the product's 36-month shelf-life.
  • Handling: The container should be kept tightly closed in a cool, dry, and well-ventilated place.
  • Child Safety: The medicine must be stored out of the sight and reach of children as a standard safety measure.

Disposal Instructions

  • Unused Product: Disposal of any unused or expired product must be carried out in accordance with local regulatory requirements.
  • Environmental Caution: It is strictly prohibited to flush Acota into the sewage system or release it into surface water, as the active substance is toxic to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acota found in:

A-Z Index: